Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · see citing works

A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma

Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768 · see citing works

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756 · see citing works

Teclistamab in Relapsed or Refractory Multiple Myeloma

Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · see citing works

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257 · see citing works

Multiple myeloma

Kumar, S. K., Rajkumar, S. V., Kyle, R. A., van Duin, M., Sonneveld, P., Mateos, M., Gay, F., & Anderson, K. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.46 · Cited by 1,235 · see citing works

Cyclophosphamide and cancer: golden anniversary

Emadi, A., Jones, R. J., & Brodsky, R. A. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.146 · Cited by 1,058 · see citing works

Diagnosis and Management of Multiple Myeloma

Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,054 · see citing works

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,027 · see citing works

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

Mateos, M., Dimopoulos, M. A., Cavo, M., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., Kaplan, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1714678 · Cited by 991 · see citing works

Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032290 · Cited by 984 · see citing works

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908 · see citing works

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900 · see citing works

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial

Facon, T. T. F., Mary, J., Hulin, C., Benboubker, L., Attal, M., Pegourié, B., Renaud, M., Harousseau, J. L., Guillerm, G., Chaleteix, C., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61537-2 · Cited by 865 · see citing works

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

Palumbo, A., Bringhen, S., Caravita, T., Merla, E., Capparella, V., Callea, V., Cangialosi, C., Grasso, M., Rossini, F., Galli, M., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68338-4 · Cited by 806 · see citing works

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Miguel, J. F. S., Weisel, K. C., Moreau, P., Lacy, M. Q., Song, K., Delforge, M., Karlin, L., Goldschmidt, H., Banos, A., Oriol, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70380-2 · Cited by 800 · see citing works

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793 · see citing works

Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma

Palumbo, A. P., Hájek, R., Delforge, M., Kropff, M. H., Petrucci, M. T., Catalano, J. V., Gisslinger, H., Wiktor-Jędrzejczak, W., Zodelava, M., Weisel, K. C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112704 · Cited by 739 · see citing works

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

Morgan, G. J., Davies, F. E., Gregory, W. M., Cocks, K., Bell, S., Szubert, A. J., Navarro-Coy, N. C., Drayson, M. T., Owen, R. G., Feyler, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)62051-x · Cited by 575 · see citing works

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial

Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 568 · see citing works

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Pasquali, S., Maqueo, J. D., Vela, J. E., Kyle, R. A., Leong, T. L., Fritz, E., Suciu, S., Palva, I. P., Oivanen, T., Corrado, C., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 547 · see citing works

HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA

McElwain, T. J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 514 · see citing works

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204925 · Cited by 487 · see citing works

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70187-x · Cited by 458 · see citing works

Clinical Pharmacokinetics of Cyclophosphamide

de Jonge, M. E., Huitema, A. D. R., Rodenhuis, S., & Beijnen, J. H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544110-00003 · Cited by 447 · see citing works

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Mateos, M., Cavo, M., Bladé, J., Dimopoulos, M. A., Suzuki, K., Jakubowiak, A. J., Knop, S. T., Doyen, C., Lúcio, P., Nagy, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32956-3 · Cited by 447 · see citing works

Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma

Kumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446 · see citing works

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8216 · Cited by 423 · see citing works

Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations

Giralt, S. A., Costa, L. J., Schriber, J. R., DiPersio, J. F., Maziarz, R. T., McCarty, J. M., Shaughnessy, P. J., Snyder, E. L., Bensinger, W., Copelan, E. A., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.10.013 · Cited by 408 · see citing works

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Usmani, S. Z., Weiss, B. M., Plesner, T., Bahlis, N. J., Belch, A., Lonial, S., Lokhorst, H. M., Voorhees, P. M., Richardson, P. G., Chari, A., et al. (2016) · Blood · doi:10.1182/blood-2016-03-705210 · Cited by 407 · see citing works

Treatment for Multiple Myeloma

Alexanian, R. (1969) · JAMA · doi:10.1001/jama.1969.03160090040009 · Cited by 395 · see citing works

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

Ramos, C. A., Grover, N. S., Beaven, A., Lulla, P., Wu, M.-F., Ivanova, A., Wang, T., Shea, T. C., Rooney, C. M., Dittus, C. E., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01342 · Cited by 389 · see citing works

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

Mateos, M., Hernández, J., Hernández, M.-T., Gutierrez, N. C., Palomera, L., Fuertes, M., Diaz‐Mediavilla, J., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-019778 · Cited by 387 · see citing works

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Cavo, M., Gay, F., Beksaç, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 381 · see citing works

Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial

Hulin, C., Facon, T. T. F., Rodon, P., Pegourié, B., Benboubker, L., Doyen, C., Dib, M., Guillerm, G., Salles, B., Eschard, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.0948 · Cited by 379 · see citing works

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Reeder, C. B., Reece, D. E., Kukreti, V., Chen, C. L., Trudel, S., Hentz, J. G., Noble, B. N., Pirooz, N. A., Spong, J., Píza, J., et al. (2009) · Leukemia · doi:10.1038/leu.2009.26 · Cited by 371 · see citing works

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00466-6 · Cited by 370 · see citing works

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

Leoni, L. M., Bailey, B., Reifert, J. R., Bendall, H. H., Zeller, R. W., Corbeil, J., Elliott, G. T., & Niemeyer, C. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1061 · Cited by 369 · see citing works

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

Palumbo, A., Bringhen, S., Liberati, A. M., Caravita, T., Falcone, A. P., Callea, V., Montanaro, M., Ria, R., Capaldi, A., Zambello, R., et al. (2008) · Blood · doi:10.1182/blood-2008-04-149427 · Cited by 357 · see citing works

Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function

Kintzel, P. E. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90010-1 · Cited by 357 · see citing works

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial

Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Hockaday, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30687-9 · Cited by 350 · see citing works

High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

Barlogie, B., Hall, R., Zander, A., Dicke, K. A., & Alexanian, R. (1986) · Blood · doi:10.1182/blood.v67.5.1298.1298 · Cited by 336 · see citing works

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

Barlogie, B., Anaissie, E. J., van Rhee, F., Haessler, J., Hollmig, K. A., Pineda‐Roman, M., Cottler‐Fox, M., Mohiuddin, A., Alsayed, Y. M., Tricot, G. J. K., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06639.x · Cited by 330 · see citing works

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Ninomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 317 · see citing works

Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

Palumbo, A. P., Falco, P., Corradini, P., Falcone, A. P., Raimondo, F. D., Giuliani, N., Crippa, C., Ciccone, G., Omedè, P., Ambrosini, M. T., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3463 · Cited by 317 · see citing works

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial

Moreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Bréchignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278 · see citing works

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

Duell, J., Dittrich, M. T., Bedke, T., Mueller, T., Eisele, F., Rosenwald, A., Rasche, L., Hartmann, E., Dandekar, T., Einsele, H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.41 · Cited by 278 · see citing works

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Facon, T., Dimopoulos, M. A., Dispenzieri, A., Catalano, J. V., Belch, A., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N. J., et al. (2018) · Blood · doi:10.1182/blood-2017-07-795047 · Cited by 271 · see citing works

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Fayers, P. M., Palumbo, A., Hulin, C., Waage, A., Wijermans, P., Beksaç, M., Bringhen, S., Mary, J., Gimsing, P., Termorshuizen, F., et al. (2011) · Blood · doi:10.1182/blood-2011-03-341669 · Cited by 271 · see citing works

Bendamustine: Rebirth of an Old Drug

Cheson, B. D., & Rummel, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.7252 · Cited by 266 · see citing works

Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma

Miguel, J. F. S., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M. H., Špıčka, I., Petrucci, M. T., Palumbo, A. P., Samoilova, O. S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6180 · Cited by 263 · see citing works

Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial

Stadtmauer, E. A., Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00685 · Cited by 259 · see citing works

Phase III Study of the Value of Thalidomide Added to Melphalan Plus Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma: The HOVON 49 Study

Wijermans, P., Schaafsma, M. R., Termorshuizen, F., Ammerlaan, R., Wittebol, S. H., Sinnige, H. A. M., Zweegman, S., Kooy, M. V. M., van der Griend, R., Lokhorst, H. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.1610 · Cited by 259 · see citing works

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

Gay, F., Musto, P., Rota-Scalabrini, D., Bertamini, L., Belotti, A., Galli, M., Offidani, M., Zamagni, E., Ledda, A., Grasso, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00535-0 · Cited by 258 · see citing works

Multiple myeloma treated with high dose intravenous melphalan

Selby, P. J., McElwain, T. J., Nandi, A., Perren, T. J., Powles, R., Tillyer, C. R., Osborne, R. J., Slevin, M. L., & Malpas, J. S. (1987) · British Journal of Haematology · doi:10.1111/j.1365-2141.1987.tb06890.x · Cited by 248 · see citing works

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma.

Waage, A., Gimsing, P., Fayers, P., Abildgaard, N., Ahlberg, L., Björkstrand, B., Carlson, K., Dahl, I., Forsberg, K., Gulbrandsen, N., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237974 · Cited by 242 · see citing works

Current status of autologous stem cell transplantation for multiple myeloma

Hamed, R. A., Bazarbachi, A. H., Malard, F., Harousseau, J., & Mohty, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0205-9 · Cited by 240 · see citing works

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

Case, D. C., Lee, B. J., & Clarkson, B. D. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90543-5 · Cited by 218 · see citing works

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival

Palumbo, A. P., Bringhen, S., Larocca, A., Rossi, D., Raimondo, F. D., Magarotto, V., Patriarca, F. F., Levi, A., Benevolo, G., Vincelli, I. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.0023 · Cited by 207 · see citing works

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

Pönisch, W., Mitrou, P. S., Merkle, K., Herold, M. J., Aßmann, M., Wilhelm, G., Dachselt, K., Richter, P., Schirmer, V., Schulze, A., et al. (2006) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0074-4 · Cited by 186 · see citing works

Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy

Facon, T. T. F. (2005) · Blood · doi:10.1182/blood-2005-04-1588 · Cited by 180 · see citing works

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial

Moreau, P., Hulin, C., Perrot, A., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Zweegman, S., Caillon, H., Caillot, D., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00428-9 · Cited by 178 · see citing works

DTPACE: An Effective, Novel Combination Chemotherapy With Thalidomide for Previously Treated Patients With Myeloma

Lee, C., Barlogie, B., Munshi, N. C., Zangari, M., Fassas, A., Jacobson, J. L., van Rhee, F., Cottler‐Fox, M., Muwalla, F., & Tricot, G. J. K. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.055 · Cited by 175 · see citing works

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

Pineda‐Roman, M., Zangari, M., Haessler, J., Anaissie, E. J., Tricot, G. J. K., van Rhee, F., Crowley, J. J., Shaughnessy, J. D., & Barlogie, B. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06921.x · Cited by 166 · see citing works

Bortezomib in combination with intermediate‐dose dexamethasone and continuous low‐dose oral cyclophosphamide for relapsed multiple myeloma

Kropff, M. H., Bisping, G., Schuck, E., Liebisch, P., Lang, N., Hentrich, M., Dechow, T. N., Kröger, N. M., Salwender, H. J., Metzner, B., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06656.x · Cited by 166 · see citing works

Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders

Yamamoto, J., Ito, T., Yamaguchi, Y., & Handa, H. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00116k · Cited by 164 · see citing works

Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma

Baz, R., Martin, T. G., Lin, H., Zhao, X., Shain, K. H., Cho, H. J., Wolf, J. L., Mahindra, A. K., Chari, A., Sullivan, D. M., et al. (2016) · Blood · doi:10.1182/blood-2015-11-682518 · Cited by 159 · see citing works

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Richardson, P. G. G., Oriol, A., Larocca, A., Bladé, J., Cavo, M., Rodríguez‐Otero, P., Leleu, X. P., Nadeem, O., Hiemenz, J. W., Hassoun, H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02259 · Cited by 157 · see citing works

Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Cook, G., Drayson, M. T., Owen, R. G., Ross, F. M., Jackson, G. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3211 · Cited by 153 · see citing works

Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study

Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedè, P., et al. (2014) · Blood · doi:10.1182/blood-2014-03-563759 · Cited by 152 · see citing works

p53 and MDM2 alterations in osteosarcomas

Lonardo, F., Ueda, T., Huvos, A. G., Healey, J. H., & Ladanyi, M. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970415)79:8 · Cited by 147 · see citing works

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma

Mai, E. K., Bertsch, U., Dürig, J., Kunz, C., Haenel, M., Blau, I. W., Munder, M., Jauch, A. T., Schurich, B., Hielscher, T., et al. (2015) · Leukemia · doi:10.1038/leu.2015.80 · Cited by 141 · see citing works

Therapy for Relapsed Multiple Myeloma

Dingli, D., Ailawadhi, S., Bergsagel, P. L., Buadi, F. K., Dispenzieri, A. A., Fonseca, R., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Kapoor, P., et al. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.003 · Cited by 140 · see citing works

CLINICAL EXPERIENCES WITH SARCOLYSIN IN NEOPLASTIC DISEASES

Blokhin, N. N., Lf, L., Переводчикова, Н. И., Chebotareva, L., & Merkulova, N. A. (1958) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1958.tb42675.x · Cited by 140 · see citing works

Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

Facon, T. T. F., Lee, J. H., Moreau, P., Niesvizky, R., Dimopoulos, M. A., Hájek, R., Pour, L., Jurczyszyn, A. J., Qiu, L., Klippel, Z. K., et al. (2019) · Blood · doi:10.1182/blood-2018-09-874396 · Cited by 129 · see citing works

CAR-T efficacy: is conditioning the key?

Neelapu, S. S. (2019) · Blood · doi:10.1182/blood-2019-03-900928 · Cited by 129 · see citing works

Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV. L-Phenylalanine mustard (NSC-8806).

Bergsagel, D. E., Cc, S., AUSTIN, C., & Griffith, K. M. (1962) · PubMed · Cited by 125 · see citing works

Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.

Boccadoro, M., Marmont, F., Tribalto, M., Avvisati, G., Andriani, A., Barbui, T., Cantonetti, M., Carotenuto, M., Comotti, B., & Dammacco, F. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.444 · Cited by 122 · see citing works

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

Lentzsch, S., O'Sullivan, A., Kennedy, R. C., Abbas, M., Dai, L., Pregja, S. L., Burt, S., Boyiadzis, M. M., Roodman, G. D., Mapara, M. Y., et al. (2012) · Blood · doi:10.1182/blood-2011-12-395715 · Cited by 119 · see citing works

Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation

Bayraktar, U. D., Bashir, Q., Qazilbash, M. H., Champlin, R. E., & Ciurea, S. O. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.08.011 · Cited by 119 · see citing works

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Zweegman, S., van der Holt, B., Mellqvist, U., Salomo, M., Bos, G. M. J., Levin, M., Visser-Wisselaar, H. A., Hansson, M., van der Velden, A. W. G., Deenik, W., et al. (2016) · Blood · doi:10.1182/blood-2015-11-679415 · Cited by 115 · see citing works

Tumor Burden Limits Bispecific Antibody Efficacy through T-cell Exhaustion Averted by Concurrent Cytotoxic Therapy

Meermeier, E. W., Welsh, S. J., Sharik, M. E., Du, M. T., Garbitt, V. M., Riggs, D. L., Shi, C., Stein, C. K., Bergsagel, M., Chau, B. H., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0038 · Cited by 112 · see citing works

Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study

Lahuerta, J. J., Mateos, M. V., Martínez‐López, J., Grande, C., de la Rubia, J., Rosiñol, L., Sureda, A. M., García‐Laraña, J., Díaz-Mediavilla, J., Hernández‐Garcia, M. T., et al. (2010) · Haematologica · doi:10.3324/haematol.2010.028027 · Cited by 111 · see citing works

Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions

Caraccio, C., Krishna, S., Phillips, D. J., & Schürch, C. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00501 · Cited by 106 · see citing works

Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients

Morgan, G. J., Schey, S., Wu, P., Srikanth, M., Phekoo, K. J., Jenner, M. W., & Davies, F. E. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06538.x · Cited by 102 · see citing works

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

Mateos, M., Oriol, A., Martínez‐López, J., Teruel, A. I., de la Guía, A. L., López, J., Bengoechea, E., Pérez, M., Martínez, R., Palomera, L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-573733 · Cited by 101 · see citing works

Phase I-II Trial of Bortezomib Plus Oral Cyclophosphamide and Prednisone in Relapsed and Refractory Multiple Myeloma

Reece, D. E., Rodriguez, G. P., Chen, C. I., Trudel, S., Kukreti, V., Mikhael, J. R., Pantoja, M. A., Xu, W., & Stewart, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2372 · Cited by 101 · see citing works

In Vitro and In Vivo Antitumor Activity of a Novel Alkylating Agent, Melphalan-Flufenamide, against Multiple Myeloma Cells

Chauhan, D., Ray, A., Viktorsson, K., Spira, J., Paba‐Prada, C. E., Munshi, N. C., Richardson, P. G. G., Lewensohn, R., & Anderson, K. C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3752 · Cited by 101 · see citing works

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma

Ludwig, H., Kasparu, H., Leitgeb, C., Rauch, E., Linkesch, W., Zojer, N., Greil, R., Seebacher, A., Pour, L., Weißmann, A., et al. (2013) · Blood · doi:10.1182/blood-2013-08-521468 · Cited by 100 · see citing works

Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas

Ghilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.521 · Cited by 99 · see citing works

Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma

Jayaweera, S. P. E., Kanakanamge, S. P. W., Rajalingam, D., & Silva, G. N. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.740796 · Cited by 98 · see citing works

Improved survival of increased-risk myeloma patients on combined triple- alkylating-agent therapy: a study of the CALGB

Jb, H., Pajak, T., McIntyre, O. R., Kochwa, S., Cooper, M., Coleman, M., & Cuttner, J. (1979) · Blood · doi:10.1182/blood.v54.1.13.13 · Cited by 97 · see citing works

Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial

Bashir, Q., Thall, P. F., Milton, D. R., Fox, P. S., Kawedia, J. D., Kebriaei, P., Shah, N. D., Patel, K. K., Andersson, B. S., Nieto, Y. L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30023-7 · Cited by 95 · see citing works

The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.

Knop, S. T., Straka, C., Haen, M., Schwedes, R., Hebart, H. F., & Einsele, H. (2005) · PubMed · Cited by 94 · see citing works

Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study

Palumbo, A., Bringhen, S., Bruno, B., Falcone, A. P., Liberati, A. M., Grasso, M., Ria, R., Pisani, F., Cangialosi, C., Caravita, T., et al. (2009) · Blood · doi:10.1182/blood-2009-09-241737 · Cited by 94 · see citing works

Melphalan 140 mg/m 2 or 200 mg/m 2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Auner, H. W., Iacobelli, S., Sbianchi, G., Knol, C., Blaise, D., Russell, N. H., Apperley, J. F., Pohlreich, D., Browne, P., Kobbe, G., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.181339 · Cited by 94 · see citing works

Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma

Magarotto, V., Bringhen, S., Offidani, M., Benevolo, G., Patriarca, F. F., Mina, R., Falcone, A. P., Paoli, L. D., Pietrantuono, G., Gentili, S., et al. (2016) · Blood · doi:10.1182/blood-2015-08-662627 · Cited by 92 · see citing works

Melflufen - a peptidase-potentiated alkylating agent in clinical trials

Wickström, M., Nygren, P., Larsson, R. L., Harmenberg, J., Lindberg, J., Sjöberg, P. J. R., Jerling, M., Lehmann, F., Richardson, P. G. G., Anderson, K. C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18420 · Cited by 89 · see citing works

Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma

Stewart, A. K., Jacobus, S. J., Fonseca, R., Weiss, M., Callander, N. S., Chanan-Khan, A. A., & Rajkumar, S. V. (2015) · Blood · doi:10.1182/blood-2014-12-613927 · Cited by 88 · see citing works

Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

Durie, B. G. M., Dixon, D. O., Carter, S. K., Stephens, R. L., Rivkin, S. E., Bonnet, J. D., Salmon, S. E., Dabich, L., Files, J. C., & Costanzi, J. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.8.1227 · Cited by 88 · see citing works

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

Mateos, M., Hernández‐Rivas, J. M., Hernández, M., Gutierrez, N. C., Palomera, L., Fuertes, M., Garcia-Sanchez, P., Lahuerta, J. J., de la Rubia, J., Terol, M. J., et al. (2008) · Haematologica · doi:10.3324/haematol.12106 · Cited by 86 · see citing works

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study

Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., Galli, M., Marcatti, M., Verde, G. L., Giuliani, N., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488676 · Cited by 85 · see citing works

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1–2 study

Richardson, P. G. G., Bringhen, S., Voorhees, P. M., Plesner, T., Mellqvist, U., Reeves, B., Paba‐Prada, C. E., Zubair, H., Byrne, C., Chauhan, D., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30044-2 · Cited by 83 · see citing works

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Schjesvold, F. H., Dimopoulos, M. A., Delimpasi, S., Robak, P., Coriu, D., Legiec, W., Pour, L., Špička, I., Masszi, T., Doronin, V., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00381-1 · Cited by 82 · see citing works

Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling

Roué, G., López‐Guerra, M., Milpied, P. J., Pérez‐Galán, P., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0388 · Cited by 82 · see citing works

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

Pönisch, W., Rozanski, M. J., Goldschmidt, H., Hoffmann, F. A., Boldt, T., Schwarzer, A., Ritter, U., Rohrberg, R., Schwalbe, E., Uhlig, J., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07076.x · Cited by 80 · see citing works

T‐cell modulation by cyclophosphamide for tumour therapy

Hughes, E., Scurr, M. J., Campbell, E., Jones, E., Godkin, A. J., & Gallimore, A. (2018) · Immunology · doi:10.1111/imm.12913 · Cited by 80 · see citing works

Melphalan in Multiple Myeloma

Hoogstraten, B., Sheehe, P. R., Cuttner, J., Cooper, T., Kyle, R. A., Oberfield, R. A., Townsend, S. R., HARLEY, J. B., Hayes, D. M., Costa, G., et al. (1967) · Blood · doi:10.1182/blood.v30.1.74.74 · Cited by 80 · see citing works

Treatment of Multiple Myeloma and the Role of Melphalan in the Era of Modern Therapies—Current Research and Clinical Approaches

Poczta, A., Rogalska, A., & Marczak, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091841 · Cited by 73 · see citing works

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Davies, F. E., Wu, P., Jenner, M. W., Srikanth, M., Saso, R. M., & Morgan, G. J. (2007) · Haematologica · doi:10.3324/haematol.11228 · Cited by 72 · see citing works

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Yimer, H. A., Melear, J. M., Faber, E. A., Bensinger, W., Burke, J. M., Narang, M., Stevens, D. A., Gunawardena, S. W., Lutska, Y., Qi, K., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.15806 · Cited by 69 · see citing works

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Radivoyevitch, T., Dean, R. M., Shaw, B. E., Brazauskas, R., Tecca, H. R., Molenaar, R. J., Battiwalla, M., Savani, B. N., Flowers, M. E. D., Cooke, K. R., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.016 · Cited by 68 · see citing works

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

Goldschmidt, H., Mai, E. K., Dürig, J., Scheid, C., Weisel, K. C., Kunz, C., Bertsch, U., Hielscher, T., Merz, M., Munder, M., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0724-1 · Cited by 67 · see citing works

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study

Chari, A., Rodríguez‐Otero, P., McCarthy, H. O., Suzuki, K., Hungria, V., Sureda, A. M., Perrot, A., Hulin, C., Magen, H., Iida, S., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16980 · Cited by 66 · see citing works

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma

Garderet, L., Kuhnowski, F., Berge, B., Roussel, M., Escoffre‐Barbe, M., Lafon, I., Facon, T. T. F., Leleu, X. P., Karlin, L., Perrot, A., et al. (2018) · Blood · doi:10.1182/blood-2018-07-863829 · Cited by 65 · see citing works

Efficacy of VDT PACE‐like regimens in treatment of relapsed/refractory multiple myeloma

Lakshman, A., Singh, P. P., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dingli, D., Hwa, Y. L., Fonder, A. L., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24954 · Cited by 64 · see citing works

CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges

Rendo, M. J., Joseph, J. J., Phan, L. M., & DeStefano, C. B. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s327016 · Cited by 64 · see citing works

Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG ‐ HD 2 trial

Mai, E. K., Benner, A., Bertsch, U., Brossart, P., Hänel, A., Kunzmann, V., Naumann, R., Neben, K., Egerer, G., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13994 · Cited by 63 · see citing works

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

Kumar, S. K., Lacy, M. Q., Hayman, S. R., Stewart, K., Buadi, F. K., Allred, J. B., Laumann, K. M., Greipp, P. R., Lust, J. A., Gertz, M. A., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22053 · Cited by 61 · see citing works

Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+ T Cells

Lu, X., Ding, Z., Cao, Y., Liu, C., Habtetsion, T. G., Yu, M., Lemos, H. D. P., Salman, H., Xu, H., Mellor, A. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401894 · Cited by 60 · see citing works

Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

Offidani, M., Corvatta, L., Maracci, L., Liberati, A. M., Ballanti, S., Attolico, I., Caraffa, P., Alesiani, F., di Toritto, T. C., Gentili, S., et al. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.58 · Cited by 60 · see citing works

Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients.

Bladé, J., Miguel, J. F. S., Alcalá, A., Maldonado, J., Sanz, M. Á., García-Conde, J., Moro, M. J., Alonso, C., Besalduch, J., & Zubizarreta, A. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.6.1165 · Cited by 59 · see citing works

Long-Term Physiological Side Effects After Allogeneic Bone Marrow Transplantation

Mohty, M., & Apperley, J. F. (2010) · Hematology · doi:10.1182/asheducation-2010.1.229 · Cited by 59 · see citing works

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma

Mateos, M., Bladé, J., Bringhen, S., Ocio, E. M., Efebera, Y. A., Pour, L., Gay, F., Sonneveld, P., Gullbo, J., & Richardson, P. G. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103120 · Cited by 58 · see citing works

Cyclophosphamide‐based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma

Tuchman, S. A., Bacon, W., Huang, L., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Chute, J. P., Sullivan, K. M., Engemann, A. M., Yopp, A., et al. (2014) · Journal of Clinical Apheresis · doi:10.1002/jca.21360 · Cited by 58 · see citing works

Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM

Mateos, M., Martínez‐López, J., Hernández, M.-T., Ocio, E. M., Rosiñol, L., Martínez, R., Teruel, A. I., Gutierrez, N. C., Ramos, M.-L. M., Oriol, A., et al. (2015) · Blood · doi:10.1182/blood-2015-08-666537 · Cited by 57 · see citing works

Bendamustine: a review of pharmacology, clinical use and immunological effects (Review)

Lalić, H., Aurer, I., Batinić, D., Višnjić, D., Smoljo, T., & Babić, A. (2022) · Oncology Reports · doi:10.3892/or.2022.8325 · Cited by 57 · see citing works

Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action

Wudhikarn, K., Wills, B., & Lesokhin, A. M. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101143 · Cited by 56 · see citing works

The mutagenic impact of melphalan in multiple myeloma

Maura, F., Weinhold, N., Diamond, B. T., Kazandjian, D. G., Rasche, L., Morgan, G. J., & Landgren, O. (2021) · Leukemia · doi:10.1038/s41375-021-01293-3 · Cited by 56 · see citing works

Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Nijhof, I. S., Franssen, L. E., Levin, M., Bos, G. M. J., Broijl, A., Klein, S. K., Koene, H. R., Bloem, A. C., Beeker, A., Faber, L. M., et al. (2016) · Blood · doi:10.1182/blood-2016-07-729236 · Cited by 55 · see citing works

Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

Swan, D., Gurney, M. E., Krawczyk, J., Ryan, A. E., & O'Dwyer, M. E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000350 · Cited by 55 · see citing works

How to Treat High-Risk Myeloma at Diagnosis and Relapse

Caro, J., Hadidi, S. A., Usmani, S. Z., Yee, A. J., Raje, N. S., & Davies, F. E. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_320105 · Cited by 55 · see citing works

Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen

Miettinen, J. J., Kumari, R., Traustadóttir, G. Á., Huppunen, M.-E., Sergeev, P., Majumder, M. M., Schepsky, A., Guðjónsson, Þ., Lievonen, J., Bazou, D., et al. (2021) · Cancers · doi:10.3390/cancers13071527 · Cited by 55 · see citing works

High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma

Lenhard, R. E., Oken, M. M., Barnes, J. M., Humphrey, R. L., Glick, J. H., & Silverstein, M. N. (1984) · Cancer · doi:10.1002/1097-0142(19840401)53:7 · Cited by 54 · see citing works

Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haemato‐Oncology (HOLA) Observational Study, 2008–2016

Hungria, V., Martinez-Banos, D. M., Peñafiel, C. O. R., Miguel, C. E., Vela‐Ojeda, J., Remaggi, G., Duarte, F. B., Cao, C., Cugliari, M. S., SANTOS, T. M. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16124 · Cited by 54 · see citing works

Melphalan hydrochloride for the treatment of multiple myeloma

Esma, F., Salvini, M., Troia, R., Boccadoro, M., Larocca, A., & Pautasso, C. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1349102 · Cited by 53 · see citing works

Phase I / II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

Berenson, J. R., Yellin, O., Bessudo, A., Boccia, R. V., Noga, S. J., Gravenor, D. S., Patel‐Donnelly, D., Siegel, R. S., Kewalramani, T., Gorak, E. J., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12129 · Cited by 52 · see citing works

Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma

Bergsagel, P. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.199 · Cited by 52 · see citing works

Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing ProdrugJ1

Gullbo, J., Wickström, M., Tullberg, M. L., Ehrsson, H., Lewensohn, R., Nygren, P., Luthman, K., & Larsson, R. L. (2003) · Journal of drug targeting · doi:10.1080/10611860310001647140 · Cited by 52 · see citing works

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.

Olivier, T., & Prasad, V. K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101374 · Cited by 51 · see citing works

High‐dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment‐related mortality in patients with multiple myeloma: results of a randomised study

Fenk, R. R., Schneider, P., Kropff, M. H., Huenerlituerkoglu, A.-N., Steidl, U. U., Aul, C., Hildebrandt, B., Haas, R. R., Heyll, A., Kobbe, G., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05641.x · Cited by 49 · see citing works

A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma

Griffin, P. T., Ho, V. Q., Fulp, W. J., Nishihori, T., Shain, K. H., Alsina, M., & Baz, R. (2015) · Cancer · doi:10.1002/cncr.29533 · Cited by 48 · see citing works

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan‐prednisone

Hjorth, M., Hellquist, L., Holmberg, E. C., Magnusson, B., Rödjer, S., Westin, J., & for the Myeloma Group of Western Sweden (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb02564.x · Cited by 48 · see citing works

Second malignancies in multiple myeloma; emerging patterns and future directions

Maclachlan, K. H., Diamond, B. T., Maura, F., Hillengaß, J., Turesson, I., Landgren, O., & Kazandjian, D. G. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101144 · Cited by 48 · see citing works

Bendamustine in patients with relapsed or refractory multiple myeloma

Michael, M., Bruns, I., Bölke, E., Zohren, F., Czibere, A. G., Safaian, N., Neumann, F., Haas, R. R., Kobbe, G., & Fenk, R. R. (2010) · European journal of medical research · doi:10.1186/2047-783x-15-1-13 · Cited by 47 · see citing works

Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myeloma

Mikhael, J. R., Reeder, C. B., Libby, E. N., Costa, L. J., Bergsagel, P. L., Buadi, F. K., Mayo, A., Reddy, S. K. N., Gano, K., Dueck, A. C., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13296 · Cited by 45 · see citing works

Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation

Costa, L. J., Iacobelli, S., Pasquini, M. C., Modi, R. A., Giaccone, L., Bladé, J., Schönland, S. O., Evangelista, A., Pérez‐Simón, J. A., Hari, P., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0887-4 · Cited by 45 · see citing works

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

Party, T. K. M. M. W., Kim, Y., Sohn, S., Lee, J.-H., Yang, D.-H., Moon, J., Ahn, J.-S., Kim, H., & Lee, J. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0856-x · Cited by 44 · see citing works

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

Damaj, G. L., Malard, F., Hulin, C., Caillot, D., Garidi, R., Royer, B., Marit, G., Stoppa, A., Baños, A., Morineau, N., et al. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.622422 · Cited by 44 · see citing works

Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma

Fenk, R. R., Michael, M., Zohren, F., Graef, T. T., Czibere, A. G., Bruns, I., Neumann, F., Fenk, B., Haas, R. R., & Kobbe, G. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701694194 · Cited by 44 · see citing works

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial

Bringhen, S., D’Agostino, M., París, L., Ballanti, S., Pescosta, N., Spada, S., Pezzatti, S., Grasso, M., Rota‐Scalabrini, D., Rosa, L. D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.226407 · Cited by 42 · see citing works

Long‐term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

Reeder, C. B., Reece, D. E., Kukreti, V., Mikhael, J. R., Chen, C. I., Trudel, S., Laumann, K. M., Vohra, H. S., Fonseca, R., Bergsagel, P. L., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.13004 · Cited by 42 · see citing works

HyperCVAD for VAD-resistant multiple myeloma

Dimopoulos, M. A., Weber, D., Kantarjian, H. M., Delasalle, K. B., & Alexanian, R. (1996) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199606)52:2 · Cited by 42 · see citing works

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma

Cho, S., Xing, L., Anderson, K. C., & Tai, Y. (2021) · Cancers · doi:10.3390/cancers13236136 · Cited by 40 · see citing works

DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma

Lazzarino, M., Corso, A., Barbarano, L., Alessandrino, E. P., Cairoli, R., Pinotti, G., Ucci, G., Uziel, L. D., Rodeghiero, F., Fava, S., et al. (2001) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703240 · Cited by 40 · see citing works

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

Pönisch, W., Bourgeois, M., Moll, B., Heyn, S., Jaekel, N., Wagner, I., Rohrberg, R., Hurtz, H.-J., Schmalfeld, M., Aßmann, M., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1339-3 · Cited by 37 · see citing works

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.247130 · Cited by 36 · see citing works

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

Rodon, P., Hulin, C., Pegourié, B., Tiab, M., Anglaret, B., Benboubker, L., Jardel, H., Decaux, O., Kolb, B., Roussel, M., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.110890 · Cited by 35 · see citing works

Bendamustine, Thalidomide and Dexamethasone is an effective salvage regimen for advanced stage multiple myeloma

Grey‐Davies, E., Bosworth, J. L., Boyd, K. D., Ebdon, C., Saso, R. M., Chitnavis, D., Mercieca, J., Morgan, G. J., & Davies, F. E. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08887.x · Cited by 35 · see citing works

An overview of the progress in the treatment of multiple myeloma

Kyle, R. A., & Rajkumar, S. V. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.870030 · Cited by 33 · see citing works

All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Dimopoulos, M. A., Grosicki, S., Wiktor-Jędrzejczak, W., Nahi, H., Gruber, A., Hansson, M., Gupta, N., Byrne, C., Labotka, R., Teng, Z., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.011 · Cited by 33 · see citing works

A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

Bensinger, W., Becker, P. S., Gooley, T. A., Chauncey, T. R., Maloney, D. G., Gopal, A. K., Green, D. J., Press, O. W., Lill, M., Ifthikharuddin, J. J., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.211 · Cited by 33 · see citing works

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

Einsele, H., Engelhardt, M. M., Tapprich, C., Müller, J., Liebisch, P., Langer, C., Kropff, M. H., Muegge, L. O., Jung, W. E., Wolf, H., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14920 · Cited by 32 · see citing works

Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma

Bringhen, S., D’Agostino, M., Paoli, L. D., Montefusco, V., Liberati, A. M., Galieni, P., Grammatico, S., Muccio, V. E., Esma, F., Angelis, C. D., et al. (2017) · Leukemia · doi:10.1038/leu.2017.327 · Cited by 32 · see citing works

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

Berglund, Å., Ullén, A., Lisyanskaya, A. S., Орлов, С. В., Hagberg, H., Tholander, B., Lewensohn, R., Nygren, P., Spira, J., Harmenberg, J., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0299-2 · Cited by 32 · see citing works

A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy

Martino, M. V., Tripepi, G. L., Messina, G., Vincelli, I. D., Console, G., Recchia, A. G., Gentile, M., Molica, S., & Morabito, F. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.94 · Cited by 32 · see citing works

Allogeneic Stem Cell Transplantation in Multiple Myeloma

Greil, C., Engelhardt, M. M., Finke, J., & Wäsch, R. (2021) · Cancers · doi:10.3390/cancers14010055 · Cited by 31 · see citing works

The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma

Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 30 · see citing works

Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis

Blommestein, H. M., van Beurden-Tan, C. H. Y., Franken, M. G., Groot, C. A. U., Sonneveld, P., & Zweegman, S. (2019) · Haematologica · doi:10.3324/haematol.2018.206912 · Cited by 30 · see citing works

Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.

Dadacaridou, M., Papanicolaou, X., Maltesas, D., Megalakaki, C., Patos, P., Panteli, K. E., Repousis, P., & Mitsouli-Mentzikof, C. (2007) · PubMed · Cited by 30 · see citing works

Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma

Pönisch, W., Holzvogt, B., Plötze, M., Andrea, M., Bourgeois, M., Heyn, S., Zehrfeld, T., Hammerschmidt, D., Schwarz, M., Edelmann, T., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1737-9 · Cited by 29 · see citing works

Weekly Cyclophosphamide and Alternate-Day Prednisone: An Effective, Convenient, and Well-Tolerated Oral Treatment for Relapsed Multiple Myeloma After Autologous Stem Cell Transplantation

Trieu, Y., Trudel, S., Pond, G. R., Mikhael, J. R., Jaksic, W., Reece, D. E., Chen, C. I., & Stewart, A. K. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1578 · Cited by 29 · see citing works

Bendamustine in multiple myeloma

Gentile, M., Vigna, E., Recchia, A. G., Morabito, L., Mendicino, F., Giagnuolo, G., & Morabito, F. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12609 · Cited by 28 · see citing works

Efficacy and Safety of Busulfan-Based Conditioning Regimens for Multiple Myeloma

Reece, D. E., Song, K., LeBlanc, R., Mezzi, K., Olujohungbe, A., White, D. J., Zaman, F., & Belch, A. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0384 · Cited by 27 · see citing works

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma

Srour, S. A., Milton, D. R., Bashir, Q., Nieto, Y. L., Saini, N. Y., Daher, M., Ramdial, J., Im, J. S., Hosing, C. M., Delgado, R., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.279179 · Cited by 27 · see citing works

Comparison of the efficiency, safety, and survival outcomes in two stem cell mobilization regimens with cyclophosphamide plus G-CSF or G-CSF alone in multiple myeloma: a meta-analysis

Wang, L., Xiang, H., Yan, Y., Deng, Z., Li, H., Li, X., & Liu, J. (2021) · Annals of Hematology · doi:10.1007/s00277-020-04376-w · Cited by 26 · see citing works

Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Mateos, M., Oriol, A., Rosiñol, L., de Arriba, F., Puig, N., Martín, J., Martínez‐López, J., Echeveste, M. A., Sarrá, J., Ocio, E. M., et al. (2015) · Haematologica · doi:10.3324/haematol.2015.124818 · Cited by 25 · see citing works

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Yong, K., Wilson, W., Tute, R. M. D., Camilleri, M., Ramasamy, K., Streetly, M. J., Sive, J. I., Bygrave, C., Benjamin, R., Chapman, M., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00350-7 · Cited by 25 · see citing works

Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma

Kazmi, S. M. A., Saliba, R. M., Donato, M. L., Wang, M., Hosing, C. M., Qureshi, S. R., Anderlini, P. N., Popat, U., Champlin, R. E., Giralt, S. A., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2010.160 · Cited by 25 · see citing works

A historical perspective on milestones in multiple myeloma research

Ribatti, D. (2017) · European Journal Of Haematology · doi:10.1111/ejh.13003 · Cited by 24 · see citing works

Perspective: An International Fludarabine Shortage: Supply Chain Issues Impacting Transplantation and Immune Effector Cell Therapy Delivery

Maziarz, R. T., Diaz, A. H., Miklos, D. B., & Shah, N. N. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.002 · Cited by 24 · see citing works

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study

Roussel, M., Lauwers‐Cancès, V., Macro, M., Leleu, X. P., Royer, B., Hulin, C., Karlin, L., Perrot, A., Touzeau, C., Chrétien, M., et al. (2022) · Blood · doi:10.1182/blood.2021014635 · Cited by 24 · see citing works

High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma

Gomez-Arteaga, A., Mark, T. M., Guarneri, D., Christos, P. J., Gergis, U. S., Greenberg, J., Hsu, J., Mayer, S. A., Niesvizky, R., Pearse, R. N., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0587-0 · Cited by 23 · see citing works

Phase 2 study of all‐oral ixazomib, cyclophosphamide and low‐dose dexamethasone for relapsed/refractory multiple myeloma

Kumar, S. K., Grząśko, N., Delimpasi, S., Wiktor-Jędrzejczak, W., Grosicki, S., Kyrtsonis, M., Spencer, A. G., Gupta, N., Teng, Z., Byrne, C., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15679 · Cited by 23 · see citing works

Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma

Kumar, S. K., Krishnan, A. Y., LaPlant, B. R., Laumann, K. M., Roy, V., Zimmerman, T. M., Gertz, M. A., Buadi, F. K., Stockerl-Goldstein, K. E., Birgin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.24181 · Cited by 22 · see citing works

Treatment May Be Harmful: Mechanisms/Prediction/Prevention of Drug-Induced DNA Damage and Repair in Multiple Myeloma

Gourzonès, C., Bret, C., & Moreaux, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00861 · Cited by 21 · see citing works

Current and Novel Alkylators in Multiple Myeloma

Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 21 · see citing works

Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients

Waal, E. G. M. D., de Munck, L., Hoogendoorn, M., Woolthuis, G., van der Velden, A. W. G., Tromp, Y., Vellenga, E., & Hovenga, S. (2015) · British Journal of Haematology · doi:10.1111/bjh.13653 · Cited by 20 · see citing works

Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial

Schey, S., Brown, S., Tillotson, A., Yong, K., Williams, C. D., Davies, F. E., Morgan, G. J., Cavenagh, J. D., Cook, G., Cook, M. A., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13435 · Cited by 20 · see citing works

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2nd‐line therapy for relapsed and refractory multiple myeloma – a phase II trial

Mey, U., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T. N., Jehner, P., Rauh, J., Taverna, C., Schmid, M., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14481 · Cited by 20 · see citing works

Bortezomib and low-dose dexamethasone with or without continuous low-dose oral cyclophosphamide for primary refractory or relapsed multiple myeloma: a randomized phase III study

Kropff, M. H., Vogel, M., Bisping, G., Schlag, R., Weide, R., Knauf, W. U., Fiechtner, H., Kojouharoff, G., Kremers, S., & Berdel, W. E. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3065-z · Cited by 20 · see citing works

SOHO State of the Art Updates and Next Questions: T-Cell–Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor–Modified T Cells and Bispecific T-Cell–Engaging Agents

Madduri, D., Dhodapkar, M. V., Lonial, S., Jagannath, S., & Cho, H. J. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.08.002 · Cited by 20 · see citing works

The role of clonal hematopoiesis as driver of therapy-related myeloid neoplasms after autologous stem cell transplantation

Gramegna, D., Bertoli, D., Cattaneo, C. M., Almici, C., Re, A., Belotti, A., Borlenghi, E., Lanzi, G., Archetti, S., Verardi, R., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04806-x · Cited by 20 · see citing works

A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma

Miguel, J. F. S., Gutierrez, M. A. E., Špıčka, I., Mateos, M., Song, K., Craig, M., Bladé, J., Hájek, R., Chen, C. I., Bacco, A. D., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.185991 · Cited by 19 · see citing works

Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias

Sridharan, A., Schinke, C., Georgiev, G. I., Ferreira, M. D. S., Thiruthuvanathan, V. J., MacArthur, I. C., Bhagat, T. D., Choudhary, G. S., Aluri, S., Chen, J., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000731 · Cited by 19 · see citing works

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Veeraputhiran, M. K., Jain, T., Deol, A., Ayash, L. J., Kim, S., Dyson, G. E., Bhutani, D., Lum, L. G., Ratanatharathorn, V., Uberti, J. P., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.05.008 · Cited by 19 · see citing works

High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma

Sivaraj, D., Bacon, W., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Sullivan, K. M., Kang, Y., Li, Z., Chao, N. J. A., & Gasparetto, C. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.208 · Cited by 19 · see citing works

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials

Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F. F., Evangelista, A., Spada, S., Benevolo, G., Oddolo, D., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.220657 · Cited by 18 · see citing works

Multiple myeloma: signaling pathways and targeted therapy

Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90 · see citing works

Podocytopathies

Romagnani, P., Tang, S. C. W., Weins, A., Huber, T. B., Osafo, C., & Anders, H. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00671-w · Cited by 27 · see citing works

Role of Immune Cells and Immunotherapy in Multiple Myeloma

Radhakrishnan, V., Golla, U., & Kudva, A. K. (2024) · Life · doi:10.3390/life14040461 · Cited by 18 · see citing works

Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy

Özgencil, F., Gunindi, H. B., & Eren, G. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107509 · Cited by 15 · see citing works

CAR T‐Cell Therapy for Multiple Myeloma: A Clinical Practice‐Oriented Review

Sadek, N. L., Costa, B. A., Nath, K., & Mailankody, S. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3057 · Cited by 13 · see citing works

Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules

Banchi, M., Cox, M. C., & Bocci, G. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216900 · Cited by 10 · see citing works

Post-Translational Modifications in Multiple Myeloma: Mechanisms of Drug Resistance and Therapeutic Opportunities

Hu, S., Xu, J., Cui, W., Jin, H.-R., Wang, X., & Maimaitiyiming, Y. (2025) · Biomolecules · doi:10.3390/biom15050702 · Cited by 9 · see citing works

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

Talarico, M., Barbato, S., Maisnar, V., Delimpasi, S., Puppi, M., Rizzello, I., Pantani, L., Tacchetti, P., Martello, M., Vigliotta, I., et al. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06326-3 · Cited by 4 · see citing works

Polymerase theta inhibition impairs tumor growth and amplifies melphalan-induced DNA damage in multiple myeloma

Li, Q., Ma, C., Zuo, L., Xu, A., Zhang, B., Zhao, F., Liu, L., Zhao, X., Hu, Y., & Sun, C. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07065-2 · Cited by 2 · see citing works

L-Sarcolysine Reduced the Mobility of Human Glioblastoma Cells, with Potential Involvement of Vimentin

Azadbeigi, P., Moosavinejad, N., & Rassouli, F. B. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s546061 · Cited by 1 · see citing works

Research Progress on Anti-tumor Mechanism of Artesunate Combined Drugs

Shi, M., & Yang, X. (2024) · Academic Journal of Science and Technology · doi:10.54097/jhbxr864 · Cited by 1 · see citing works

Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies

Cracchiolo, M. J., Davis, L. E., Matiatos, A. P., Davini, D. W., Husnain, M., Simpson, R. J., Voudouris, V., & Katsanis, E. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04688-y · Cited by 1 · see citing works

Melphalan improves toxicity of arsenic trioxide in adult T-cell leukemia/lymphoma cells

Khodadadi, F., Sadeghian, M. H., Delbari, Z., Kazemi, M., Koohpaykar, H., & Rassouli, F. B. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102109 · Cited by 1 · see citing works

Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias

Wagner, C. B., Julian, K. L., Bryan, B., Steinbach, M. N., Shewan, S., Maxwell, L., Vigil, M., Mohyuddin, G. R., Godara, A., McClune, B. L., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2350670

Anticancer Drug Utilization and Prescription Practices in a Saudi Cancer Center (2014-2022)

Badheeb, A. M., Munjem, M. F. A., Ahmed, F., Aljedaani, H., Assiri, N., Abdulaziz, A., Abubakar, A., AlQurayshah, M., & Badheeb, M. A. (2025) · F1000Research · doi:10.12688/f1000research.147910.2

Burden of multiple myeloma in Asian countries from 1990 to 2021 and trend prediction for 2050: an analysis based on the Global Burden of Disease Study 2021

Hu, C., Chen, W., Zhang, P., Shen, T., & Zhao, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1696768

Risk for second primary malignancies in patients with multiple myeloma: a systematic review and meta-analysis

Tian, Y., Su, L., Li, Y., Ye, M., Zhang, Y., Li, Q. Q., Jiao, Y., & Wu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1770120

Periplocin targets STAT3 to suppress MYC expression and inhibit multiple myeloma cell proliferation

Wei, R.-F., Chen, J., Lai, S.-P., Chen, Z.-A., Zhou, Y.-Y., Liao, Y.-P., & Chen, Y. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.07.002

Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence

Akrawi, D., Datta, S., Hatipoğlu, S., Wechalekar, A. D., Ghose, A., Alkhateeb, A., Walker, J. M., & Ghosh, A. K. (2026) · Current Cardiology Reports · doi:10.1007/s11886-026-02397-x

Current and Novel Alkylators in Multiple Myeloma

Schjesvold, F. H., & Oriol, A. (2021) · Cancers · doi:10.3390/cancers13102465 · Cited by 21 · see citing works

The Evolving Role of Alkylating Agents in Multiple Myeloma: From the Past and Present to Next-Generation Peptide Drug Conjugates

Liu, Y., Hossain, S., Nadeem, O., Midha, S., Hartley-Brown, M., Salman, T., Vianna, P., Sperling, A. S., Bianchi, G., Mo, C. C., et al. (2025) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2025.24.180

Chemotherapy-based regimens in multiple myeloma in 2020

Gentile, M., Morabito, F., Martino, M. V., Vigna, E., Martino, E. A., Mendicino, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04145-2 · Cited by 17 · see citing works

Is there a role for new drugs with alkylating properties in multiple myeloma?

Mateos, M., & González‐Calle, V. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30073-9 · Cited by 2 · see citing works

Evolving therapeutic paradigms for multiple myeloma: back to the future

Cherry, B. M., Korde, N., Kwok, M., Roschewski, M. J., & Landgren, O. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.717277 · Cited by 16 · see citing works